Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a pivotal programme in 2025.

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drug-maker Pfizer announced Saturday.

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically meaningful, and Pfizer is now thinking about starting a phase 3 programme for the drug next year.

Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal trial program.

Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition. In

Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.